Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Offene Verlängerungsstudie zur Bewertung von GLM101 bei PMM2-CDG-Patienten

22. Oktober 2026 aktualisiert von: Glycomine, Inc.

Eine offene Phase-2-Verlängerungsstudie zur Bewertung der Sicherheit und Wirksamkeit von GLM101, das Teilnehmern mit PMM2-CDG intravenös verabreicht wird

The goal of this clinical trial is to provide continued access to GLM101 to treat PMM2-CDG in people who have previously received GLM101 in other trials and learn about the long term effect of GLM101. Participants will complete weekly infusions of GLM101 at the same dose level received in previous trials.

Studienübersicht

Status

Anmeldung auf Einladung

Intervention / Behandlung

Detaillierte Beschreibung

This is a phase 2 open-label clinical study of GLM101 in patients with PMM2-CDG who have previously participated in a study of GLM101. This study is designed to monitor long-term safety and treatment effect of GLM101 and provide continued access to study treatment. Participants will receive 30 mg/kg. Dose levels may be adjusted to lower doses or higher doses based on available data that demonstrates a change to be safe and favorable. Among other assessments, participants will be asked to complete questionnaires to evaluate changes in ataxia and quality of life.

Studientyp

Interventionell

Einschreibung (Geschätzt)

90

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Münster, Deutschland, 48149
        • Universitaetsklinikum Münster
      • Paris, Frankreich, 75015
        • AP-HP Hopital Universitaire Necker-Enfants Malades
      • Catania, Italien, 95124
        • Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco - Presidio Ospedaliero G. Rodolico
      • Pisa, Italien, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Porto, Portugal, 4099-001
        • Unidade Local de Saúde de Santo António, E.P.E
      • Esplugues de Llobregat, Spanien, 08950
        • Hospital Sant Joan de Déu
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre
      • Madrid, Spanien, 28041
        • Hospital Universitario 12 de Octubre - Unidad Pediatrica de Investigacion y Ensayos Clinicos (UPIC)
      • Prague, Tschechien, 128 08
        • Vseobecna fakultni nemocnice v Praze
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55455
        • University of Minnesota
    • New York
      • New York, New York, Vereinigte Staaten, 10029
        • The Icahn School of Medicine at Mount Sinai
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • The Children's Hospital of Philadelphia (CHOP)
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98105
        • Seattle Children's Hospital
      • Birmingham, Vereinigtes Königreich, B4 6NH
        • Birmingham Children's Hospital
      • London, Vereinigtes Königreich, WC1N 3JH
        • Great Ormond Street Hospital for Children

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

2 Jahre und älter (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Is willing and able to provide informed consent/assent, directly or through a legally authorized representative.

  2. Has successfully completed the Treatment Period with GLM101 in a previous clinical study.

  3. At least 2 years of age, at the time of signing the informed consent form (ICF).

  4. Molecularly confirmed diagnosis of PMM2-CDG. Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND phosphomannomutase-2 (PMM2) enzyme activity consistent with a diagnosis of PMM2-CDG. Historical diagnosis including from a prior parent trial is permitted;

  5. Male or female participant has appropriate measures in place to prevent pregnancy:

    • If the participant is a female of childbearing potential (i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy)) or becomes of childbearing potential during the study, she must not be pregnant (confirmed by a negative serum pregnancy test), is using a medically accepted method of contraception (abstinence, a hormonal contraceptive associated with inhibition of ovulation in conjunction with a barrier method, or use of an intrauterine device), and must agree to continue using this method for 50 days after the last infusion of GLM101. Note: True abstinence: defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
    • If the participant is a female of non-childbearing potential, she must be pre-pubertal, surgically sterile, or must have an ovarian dysfunction confirmed by a follicle stimulating hormone (FSH) >40 IU/L and absence of menses for 12 months without an alternative medical cause.
    • If the participant is a sexually active (or becomes sexually active during the study) male with female partners, the sexually mature, nonsterile male participant agrees to use a medically acceptable method of contraception (abstinence, the partner taking a hormonal contraceptive in conjunction with a male condom, or use by the partner of an intrauterine device with a male condom) and agrees to continue using this method for 50 days after the last infusion of GLM101. Males are considered surgically sterile if they have undergone bilateral orchiectomy or vasectomy at least 3 months prior to Screening.
  6. If the participant is male, he must agree to refrain from donating sperm during the study and 50 days after the last infusion of GLM101.

  7. Is willing and able to comply with this protocol.

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from participation in the study:

  1. Has any other condition that would, in the opinion of the Investigator, potentially compromise the safety or compliance of the participant or preclude the participant's successful completion of the study.
  2. Diagnosis of congenital disorder of glycosylation (CDG) other than PMM2; Diagnosis is defined as biallelic pathogenic and/or likely pathogenic variants, or, in the case of variants of uncertain pathogenicity, demonstration of bi-allelic variants AND the defined CDG enzyme activity consistent with a diagnosis of the CDG other than PMM2 CDG.
  3. If not enrolling directly from a parent study (i.e., more than 28 days from Final Treatment visit in a parent study to date of consent), has an active infection requiring parenteral antibiotics, antivirals, or antifungals or treatment with systemic steroids within 7 days prior to Screening;
  4. ALT or AST >3× ULN OR total bilirubin >2× ULN or INR >1.5 (if no anti-coagulation treatment) or INR > 4 (if participant on anti-coagulation treatment) considered clinically significant;
  5. Has a history of liver transplant;
  6. Has a history of drug or alcohol use disorder within the 12 months prior to Screening;
  7. If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has had a major surgical procedure within 30 days prior to Screening;
  8. Has laboratory value(s) outside the laboratory reference range considered clinically significant and not related to PMM2-CDG;
  9. If female, has a positive serum pregnancy test during Screening.
  10. If female, and breastfeeding.
  11. Is currently participating in another interventional clinical study or has completed another clinical study with an investigational drug or device (other than GLM101) within 30 days or 5 half-lives before GLM101 infusion.
  12. Has a hypersensitivity to anti-histamine pre-medication.
  13. Has a history of a severe allergic reaction to any drug or excipients of GLM101 (as listed in the GLM101 IB);
  14. If not enrolling directly from a parent study (i.e., if more than 28 days from Final Treatment visit in a parent study to date of consent), has serology positive for hepatitis B surface antigen or hepatitis C antibody during Screening;
  15. Has a QTc ≥ 450 ms, or other clinically significant ECG abnormalities;
  16. Has uncontrolled cardiovascular, hepatic, pulmonary, gastro-intestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric or other significant disease;
  17. Weight exceeds 120 kg.
  18. Persons who have been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  19. Participant is unwilling or unable to comply with scheduled visits, study drug administration plan, laboratory tests, other study procedures, and study restrictions.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: 30 mg/kg GLM101

GLM101 IV infusions, given weekly

GLM101 IV infusion

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Evaluate long-term safety
Zeitfenster: From enrollment to end of treatment up to 4 years

Number of participants with treatment related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

From enrollment to end of treatment up to 4 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Evaluate changes in ataxia using International Cooperative Ataxia Rating Scale (ICARS)
Zeitfenster: From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years

The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.

From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years
Maximum observed plasma concentration (Cmax)
Zeitfenster: From enrollment to end of treatment up to 4 years

Assessment of the pharmacokinetics (PK) of GLM101

From enrollment to end of treatment up to 4 years
Time to maximum observed plasma concentration (Tmax)
Zeitfenster: From enrollment to end of treatment up to 4 years

Assessment pharmacokinetics (PK) of GLM101

From enrollment to end of treatment up to 4 years
Area under the plasma concentration vs. time curve (AUC)
Zeitfenster: From enrollment to end of treatment up to 4 years

Assessment of the pharmacokinetics (PK) of GLM101

From enrollment to end of treatment up to 4 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Chief Medical Officer, Glycomine, Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

30. September 2024

Primärer Abschluss (Geschätzt)

1. September 2029

Studienabschluss (Geschätzt)

1. Oktober 2029

Studienanmeldedaten

Zuerst eingereicht

22. Oktober 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. Oktober 2024

Zuerst gepostet (Tatsächlich)

26. Oktober 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

23. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

22. Oktober 2026

Zuletzt verifiziert

1. Juli 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • GLM101-007

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren